Synlogic, Inc. (SYBX) stock
Close on Oct 19, 2026Market cap $13.29MP/E –Yield –
Synlogic, Inc. reported revenue of $0 for the twelve months to Sep 30, 2026. Free cash flow was -$4.36M. At the latest close the market valued the company at $13.29M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $13.29M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.31
- Dividend yield
- –
- Free cash flow yield
- -32.80%
Fundamentals
- Revenue
- $0
- Net income
- -$2.23M
- EPS, diluted
- -$0.18
- Free cash flow
- -$4.36M
- Book value per share
- $0.82
- Diluted shares
- 12M
Trading
- Previous close
- $1.00
- Open
- $0.96
- Day's range
- $0.96 – $1.07
- Volume
- 11,177
- Average volume (20 days)
- 36,574
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | SYBX | S&P 500 | Difference | SYBX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -10.1% | +0.6% | −10.7 pts | ||
| 3 months | +46.0% | +3.4% | +42.6 pts | ||
| Year to date | -4.5% | +13.3% | −17.7 pts | ||
| 1 year | -41.5% | +16.6% | −58.1 pts | ||
| 3 years | -53.5% | +86.4% | −139.9 pts | -22.5% | +23.1% |
| 5 years | -97.2% | +81.9% | −179.1 pts | -51.2% | +12.7% |
| 10 years | -99.4% | +318.9% | −418.2 pts | -39.7% | +15.4% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Synlogic filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Results
- Results
- Results
- News
About Synlogic
Pharmaceutical Preparations
Synlogic, Inc. is a biopharmaceutical company that formerly developed novel therapeutics using synthetic biology to treat serious illnesses, specifically rare metabolic diseases. The company’s pipeline centered on genetically engineered bacterial therapeutics, known as Synthetic Biotics, designed to target conditions such as phenylketonuria, homocystinuria, hyperoxaluria, hyperuricemia, and hyperammonemia, along with inflammatory and autoimmune disorders. Following the discontinuation of its lead clinical study, Synlogic operates as a public shell company whose primary activities involve reviewing strategic alternatives, which include potential mergers or an outright sale of the business.
Company profile, executives and historySynlogic stock: common questions
What is Synlogic's stock price?
SYBX closed at $1.07 on Oct 19, 2026, up 7.00% on the day.
What is Synlogic's market cap?
Synlogic was worth $13.29M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is SYBX's P/E ratio?
Synlogic lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.18), so it has no meaningful P/E ratio.
How much revenue does Synlogic make?
Synlogic reported revenue of $0 for the twelve months to Sep 30, 2026.
Does Synlogic pay a dividend?
No. Synlogic has not paid a cash dividend over the last twelve months.
How has SYBX stock performed over the past year?
Including dividends, SYBX returned -41.5% over the past year, against +16.6% for the S&P 500.
Who are Synlogic's competitors?
Companies most similar to Synlogic by business, industry and size include AZTR, TCRT, CRVO, GNLX, KPRX.
See a number that looks wrong?